Tucatinib (Tukysa) is a new-generation HER2-targeted therapeutic agent that has demonstrated significant efficacy in the treatment of HER2-positive metastatic breast cancer and colorectal cancer. As a strictly regulated prescription medication, patients must follow professional medical guidance when purchasing, storing, and using it.

How to Purchase Tucatinib (Tukysa)

Overseas Purchase

Patients may choose to consult and purchase Tucatinib at hospital pharmacies or authorized drugstores in countries or regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions typically provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchasing Tucatinib (Tukysa)

Prescription Compliance Requirements

As a strictly regulated prescription drug, Tucatinib must be purchased with a valid prescription issued by a physician.

Any purchase without a prescription poses serious health risks.

Standardized Dosage Management

Standard dosage: The recommended adult dosage is 300 mg taken orally, twice daily.

Special populations: For patients with severe hepatic impairment, the recommended dosage is 200 mg taken orally, twice daily.

Combination therapy: For breast cancer, it must be used in combination with trastuzumab and capecitabine; for colorectal cancer, it must be used in combination with trastuzumab.

Contraindications for Special Populations

Pregnant women: Use is explicitly contraindicated, as it may cause harm to the fetus.

Lactating women: Breastfeeding is not recommended during treatment and for 1 week after the last dose.

Hepatic and renal function: Dosage adjustment is required for patients with severe hepatic impairment; extreme caution is needed when using capecitabine in patients with severe renal impairment.

Methods to Identify the Authenticity of Tucatinib (Tukysa)

Verification of Packaging Information

Approval number verification: The official FDA-approved registration number must be checked.

Manufacturer confirmation: The manufacturer and distributor is Seagen Inc.

Anti-counterfeiting labeling: The label must clearly state "Store in the original container to protect from moisture".

Comparison of Drug Appearance Characteristics

50 mg tablet characteristics: Yellow film-coated round tablets, engraved with "TUC" on one side and "50" on the other.

150 mg tablet characteristics: Yellow film-coated oval tablets, engraved with "TUC" on one side and "150" on the other.

Professional Institution Certification

Professional identification by the attending physician or pharmacist.

Confirmation of official channels through hospital pharmacies or medical institutions.

Inquiry of formal registration records from drug regulatory authorities.